Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors

Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors

Item
http://www.wikidata.org/entity/Q28085415
In Vitro and In Vivo Models for the Study of Human Polyomavirus InfectionProgressive multifocal leukoencephalopathy after heart transplantation: 4 years of clinically stable infection on low-dose immunosuppressive therapy.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Definition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance.Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectivenessp53 elevation in human cells halt SV40 infection by inhibiting T-ag expression.Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.Reducing persistent polyomavirus infection increases functionality of virus-specific memory CD8 T cells.Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
P2860

Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors

Item
http://www.wikidata.org/entity/Q28085415
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Immune System Involvement in t ...... and Therapies as Risk Factors
@ast
Immune System Involvement in t ...... and Therapies as Risk Factors
@en
Immune System Involvement in t ...... and Therapies as Risk Factors
@nl
type
label
Immune System Involvement in t ...... and Therapies as Risk Factors
@ast
Immune System Involvement in t ...... and Therapies as Risk Factors
@en
Immune System Involvement in t ...... and Therapies as Risk Factors
@nl
prefLabel
Immune System Involvement in t ...... and Therapies as Risk Factors
@ast
Immune System Involvement in t ...... and Therapies as Risk Factors
@en
Immune System Involvement in t ...... and Therapies as Risk Factors
@nl
P1433
P1476
P2093
P2860
P304
P31
P3181
P356
P407
P478
P577
P5875
P698
P921
P932
P3181
P356
P1433
P1476
Immune System Involvement in t ...... and Therapies as Risk Factors
@en
P2093
P2860
P304
P31
P3181
P356
P407
P478
P577
P5875
P698
P921
P932